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Abstract
We wanted to evaluate the prognostic value of common histopathological variables in a large cohort of patients with
cancer in the mobile tongue as such information can be important for treatment stratification of the individual patient,
especially for patients with low-stage disease. In addition, we wanted to investigate whether an alternative scoring model
with fewer options would compromise the prognostic value. One hundred fifty patients with oral tongue squamous cell
carcinomas that were treated in curative intent and with available HE-stained tumor sections were included. We
reclassified all tumors and performed univariate and multivariate survival analyses of histopathological and clinical
variables. For the complete cohort, lymph node status, grade of differentiation, perineural infiltration, and lymphocytic
infiltration were independent prognosticators. In the low-stage disease group, independent prognostic factors were tumor
size, grade of differentiation, and lymphocytic infiltrate. For patients with low-stage disease, a histo-score combining the
scores for tumor differentiation and lymphocytic infiltrate identified a group of patients with particularly low survival, as
patients with moderately or poorly differentiated tumors and little lymphocytic infiltrate had a less favorable 5-year
survival outcome than patients in the high-stage disease group. This study shows that a histo-score combining tumor
differentiation and lymphocytic infiltration should be given special consideration in treatment planning. Our results also
illustrate that many variables can be scored with fewer options than previously suggested to increase their reproducibil-
ity, and still maintain their prognostic value.
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About half of all malignant tumors in the oral cavity arise in the
mobile, anterior two-thirds of the tongue, and more than 90% of
themare squamouscell carcinomas (SCC) [1].Theaggressiveness
of oral cavity tongue (OT) SCC varies markedly, even for small
tumors without lymph node metastases [2]. The search for mor-
phological tumor traits that reliably predict the prognosis for the
individual patient has beengoingon for decades [3–5]. Suchprog-
nosticmarkerscouldhelpcliniciansselect theoptimal treatment for
individualpatients thatcould increase thechancesofbeingcuredof
the disease, and at the same time minimize the side effects from
overtreatment. The TNM system classifies tumors based on their
size and depth of invasion (T), neck node involvement (N), and
distantmetastasis (M).Alongwith the InternationalUnion against
cancer (UICC) staging, these factors are today the best survival
prognosticators for cancers in the oral cavity [6]. On the group
level, patients with low-stage disease (stages I–II; T1–2, N0M0)
haveanestimatedhigher survival rate comparedwithpatientswith
high-stage disease (stages III–IV) [7, 8]. However, there is a need
to findmarkers that candifferentiate between aggressive andmore
indolent tumors for individual patients within the same stage.
Various aspects of a tumor’s morphology and growth pattern
can be evaluated on hematoxylin and eosin (HE)-stained tumor
sections. Several of these characteristics have been proposed as
prognostic markers in oral cancer [4, 9, 10]. However, despite
some reports of prognostic usefulness, none of these markers has
been implemented in clinical practice, mostly due to lack of co-
herence between studies. There are several putative explanations
for the lack of consistency between prognostic studies. Many are
based on small patient cohorts and do not control for parameters
known to affect prognosis, such as intraoral location and stage
[11–14]. This biases the actual prognostic value of the markers
in question. Furthermore, the evaluation of histopathological
criteria is subjective, and different pathologists may interpret the
samecriteriondifferently [15,16]. Ina recentstudy,wefoundpoor
inter- and intra-observer agreementwhen evaluating a selection of
proposed histopathological prognostic markers in oral SCC, even
though the observers hadmutual training sessions andwere expe-
rienced pathologists [17]. Improved agreement was obtained by
reducing the number of scoring alternatives for each parameter.
This suggests that feweroptions foreachparametermight increase
the robustness of histopathological prognostic markers, provided
that the reduction of scoring alternatives does not compromise the
prognostic value. In the current study,weevaluated theprognostic
value of a number of proposed histopathological variables as they
were originally proposed, as well as with a reduced number of
scoring alternatives, in a large, homogenous cohort of OTSCC.
Our results show that somehistopathologicalmarkers, individual-
ly and in combination, can add significant prognostic information
for OTSCC. Our study further highlights the importance of
controlling for known risk factors such as tumor size and lymph
node metastasis when evaluating putative prognostic markers.
Materials and methods
Cohort of patients
The Norwegian Oral Cancer (NOROC) study is a retrospective
study that includes patients diagnosed with oral cavity SCC in
Norway from January 1, 2005, through December 31, 2009.The
NOROC study includes patients with strict oral cavity SCC [8].
In the present study, the relevant ICD-10 codes were C02, which
refer to cancers in the mobile tongue. Of the original NOROC
cohort, 273 patients (45%) hadOTSCC. From them,we included
only the primary, treatment-naïve patients who were treated in
curative intent and fromwhomwe had HE-stained sections from
biopsies or resections available, altogether 150 patients.
Extracting clinical and histopathological data
Experienced head and neck surgeons retrieved clinical parame-
ters from the electronic health records as previously described
[8]. Of the 150 patients that underwent surgery, 72 patients had
neck surgery, and for them, the N-status was based on histopath-
ological evaluation. For the patients who did not have neck sur-
gery, the N-status was based on clinical/radiological evaluation.
Senior pathologists re-evaluated the histopathological char-
acteristics of the tumors, including WHO degree of differen-
tiation, keratinization, nuclear polymorphism, perineural infil-
tration, lymphocyte infiltrate at the interface between tumor
and surrounding stroma, and worst pattern of invasion [3, 4].
For several of these, a fairly elaborate grading system was
originally suggested. In this study, we have also applied alter-
native versions, as described in our previous paper [17] and
summarized in Table 1. The pathologists were blinded for the
patients’ clinical information and outcome.
We calculated survival from the date of diagnosis until the
date of death or last day of follow-up, which was June 1, 2015.
At that time, all patients were followed up for a minimum of
5 years or until death. Cause of death was acquired from the
Norwegian Cause of Death Registry.
The studywas approved by the Northern Norwegian Regional
Committee for Medical Research Ethics (Protocol numbers REK
Nord; 2013/1786 and 2015/1381). Patients still alive were in-
formed about the project and had the opportunity to opt-out.
Statistical analysis
Descriptive analyses and univariate survival analyses using
log-rank (Mantel-Cox) giving Kaplan-Meier survival curves
were performed. Variables significant in univariate calcula-
tions were tested for collinearity before entering them into
multivariable equations. Multivariate survival analyses were
performed using Cox regression model. Associations were
investigated using chi-square. Receiver operating characteris-
tic curve was applied to evaluate cut-off values in binary
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classifications. All statistical analyses were performed using
SPSS version 26. All survival analyses were significant at
0.05 level.
Results
One hundred and fifty patients with OTSCC were eligible
for histopathological reclassification and included in the
study. Of the tumor material available, 127 were resection
specimens, 18 biopsies, and 5 unknown. Seventy-seven
patients had low-stage disease (stages I and II according
to TNM 8th edition), 63 had high-stage (stages III and IV)
[6], and for 10 cases the information for stage was
missing.
Supplementary Table 1 presents the scores for each vari-
able for the whole cohort and after separation into low-stage
and high-stage disease. Table 2 presents gender, age, TNM-
status and stage, as well as calculation of 5-year disease-
specific survival (DSS).
Table 1 Variables with original
and alternative grading Tumor characteristics Original variables Alternative 1 Alternative 2
1.0 Differentiation whole tumor Well 1.1 Low-grade
Moderate
Poorly High-grade
2.0 Differentiation worst pattern Well 2.1 Low-grade
Moderate
Poorly High-grade
















7.0 Perineural infiltration None 7.1 No
Invasive front Yes
Tumor center
8.0 Lymphocyte infiltrate Marked 8.1 Marked 8.2 Abundant
Moderate Not marked
Little/none Little





*According to Bryne et al. [3]
**According to Brandwein-Gensler et al. [4]. Type 1 pushing borders; Type 2 finger-like growth pattern; Type 3
large separate islands, > 15 cells per island; Type 4 small tumor islands, ≤ 15 cells per island; Type 5 tumor
satellites, ≥ 1 mm from main tumor/satellite
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Survival
The 5-year DSS was 64.8% for the whole group and 82.8%
and 44.6% for the low- and high-stage group, respectively.
Univariate analyses
In Table 3, 5-year DSS from univariate analyses are listed for
each variable, both with original and alternative versions of
grading. For the whole cohort, the following variables were
significantly associated with 5-year DSS: degree of differen-
tiation (1.0 and 1.1), keratinization of the whole tumor (3.0
and 3.1), keratinization at tumor front (4.0 and 4.1), perineural
infiltration (7.0 and 7.1), lymphocytic infiltrate (8.0, 8.1, and
8.2), and worst pattern of infiltration (9.2).
For patients with low-stage disease, differentiation of the
whole tumor (1.0 and 1.1), nuclear polymorphism whole tu-
mor (5.0 and 5.1), nuclear polymorphism at tumor front (6.1),
and lymphocytic infiltrate (8.0, 8.1, and 8.2) were significant-
ly associated with DSS. For patients with high-stage disease,
differentiation of whole tumor (1.1) and perineural infiltration
(7.0) were the only significant prognosticators of DSS.
Separate calculations were also performed for resection
specimens only (biopsies excluded) with results similar to
those for all tumors (resections and biopsies), and it is present-
ed in Supplementary Table 2.
Multivariate analyses
We performed multivariate analysis of the histopathological
variables that were significant in univariate calculations, with
separate analyses for original and alternative grading of the
variables. Additionally, T and lymph node status was included
in the equation for the whole cohort, and T for the low-stage
disease group. For the whole cohort, this included differenti-
ation, keratinization, perineural infiltration, and lymphocytic
infiltration for both original and alternative scoring gradings,
and WPOI was additionally included in the alternative ver-
sion. Keratinization of the whole tumor and keratinization of
the tumor front were collinear, and only keratinization of the
whole tumor (3.0/3.1) was included in multivariate analyses.
For patients with low-stage disease differentiation, nuclear
polymorphism and lymphocytic infiltration were included.
Nuclear polymorphism of the whole tumor and in the tumor
front were collinear, and only polymorphism of whole tumor
(5.0/5.1) was included in the multivariate analyses.
Independent prognosticators for the complete patient cohort
were lymph node status (N, p < 0.001), differentiation of
whole tumor (1.1, p = 0.022), perineural infiltration (7.0,
p = 0.025), and lymphocytic infiltration (8.2, p = 0.048). In
the low-stage group, T (p = 0.003), differentiation of whole
tumor (1.1, p = 0.022), and lymphocytic infiltrate (8.2, p =
0.003) were all independent variables.
Combined histo-score
For the low-stage group, we created a combined score, called
histo-score, based on tumor differentiation and lymphocytic
infiltrate (Fig. 1). The histo-score was calculated by summa-
rizing the individual score of differentiation and lymphocyte
infiltration (Supplementary Table 3). Using the original grad-
ing, the lowest score was 2 and the highest was 6. There was a
highly significant difference in survival between the groups
(p < 001), Fig. 2. Of the 48 patients with scores 2, 3, or 4, only
two patients died of the disease within 5 years (DSS = 95.8%).
Of the 14 patients with a score of 5 or 6, eight patients died
within 5 years (DSS 42.9%). The area under the ROC curve
was estimated to be 0.748. The combined histo-score based on
the alternative grading differentiation 1.1 and lymphocytic
infiltration 8.2 showed the same significant prognostic power
(p < 0.001).
There were no common denominators for the patients with
low-stage disease and low versus high histo-score who died
with respect to age, gender, T-stage, keratinization, or worst
pattern of infiltration. Additionally, we exploredwhether there
was a difference between different treatment options (with or
without neck dissection, with or without postsurgical radio-
therapy), but we could not find any associations.
Table 2 Clinicopathological characteristics related to 5-year disease
specific survival (DSS). Number and percent of patients in each group,
and in addition percentage of patients with 5-year DSS
Variable n % DSS % p *(DSS)
Gender Male 92 61.3 70.7 0.702
Female 58 38.7 69.0
Age (year) group ≤ 50 29 19.3 79.3 0.015
51–60 29 19.3 65.5
61–70 44 29.3 70.5
71–80 31 20.7 67.7
≥ 81 17 11.3 64.7
pT 8th Edition pT1 48 35.6 87.5 0.006
pT2 53 39.3 64.2
pT3 34 25.2 64.7
N** N0 108 72.0 82.4 0.001
N+ 40 26.7 37.5
Nx/Unknown 2 1.3
Stage Low stage 77 55.0 82.8 < 0.001
High stage 63 42.0 44.6
Nx/Unknown 10 6.7
*Significant at 0.05 level
**Combination of cN and pN. If neck dissection was performed the result
on pN was superior to cN
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Discussion
Reliable, prognostic markers that can supplement tumor staging
are lacking for oral cavity cancer. As tumors of the same stage
can have different degrees of aggressiveness, there is a need to
find additional markers to assist the treatment planning and to
predict the outcome of individual patients. Oral cancer is most
prevalent in developing countries [18]. Thus, markers that do not
require expensive equipment or reagents, such as histopatholog-
ical traits that can be assessed on HE-stained sections, are espe-
cially valuable. In the present study, we have evaluated the prog-
nostic power of a number of histopathological variables sug-
gested for oral cancer, where results from previous studies are
contradictory [19, 20]. We have tested them in a large, homog-
enous cohort of patients with OTSCC, in which clinical and
histopathological parameters are well controlled. Our hypothesis
was that the lack of consistency of prognostic value in previous
studies can be partly explained by small cohorts of patients and
the inclusion of tumors from various intraoral locations.
Furthermore, scoring of histopathological parameters is subjec-
tive, as reflected by the poor inter- and intra-rater agreement [17].
Several of the histological variables have been proposed with
three to six options for scoring, sometimeswith subtle differences
between each alternative. Grouping categories and thereby re-
ducing the number of scoring alternatives can make the scoring
easier and more reproducible [17]. Therefore, we also tested the
prognostic power of the variables as they were originally pro-
posed, as well as with broader and fewer categories.
As expected, the well-established prognostic markers’ tumor
size and lymph node metastases were independent predictors of
survival. Additionally, we found that tumor differentiation was
an independent prognosticator of survival both for the whole
cohort and for patients with low-stage disease. WHO lists differ-
entiation as a prognostic marker for oral cavity cancer, and the
degree of differentiation is usually described in pathology reports
[21]. However, due to many studies reporting low prognostic
value of differentiation for oral SCC, clinicians rarely give it
much emphasis during treatment planning [22, 23]. Our results
indicate that this marker has significant prognostic power.
A revised grading for lymphocytic infiltration where the cat-
egories for marked and moderate infiltration were combined was
also an independent prognostic marker for low-stage disease and
Table 3 Variables (both original and alternative grading) and 5-year disease-specific survival in univariate calculations for the whole cohort, and for
low-stage disease and high-stage disease separately. The percentage of patients surviving according to different grading is specified under DSS%
Whole cohort (n = 150) Low-stage (n = 78) High-stage (n = 63)
Variables All All All





94.7/84.6/40.0 0.002 (63)* 75.0/47.7/0 0.055 (55)
1.1 70.4/16.7 < 0.001* 87.7/40.0 0.001* 51.1/0 0.025 *
2.0 Differentiation,
worst pattern
100/72.0/56.7 0.074 (124) 100/88.9/76.9 0.248 (63) 100/50.0/40.0 0.646 (54)
2.1 75.4/56.7 0.053 90.9/76.7 0.121 52.6/40.0 0.676
3.0 Keratinizationwhole tumor 85.0/68.0/53.6/47.6 0.038 (124)* 82.4/91.3/83.3/66.7 0.402 (61) 83.3/46.2/30.8/22.2 0.137 (54)
3.1 73.3/51.0 0.010 * 87.5/76.2 0.238 53.1/27.3 0.078
4.0 Keratinization, tumor front /100/70.3/59.7 0.047 (120)* ÷/100/89.5/75.8 0.133 (62) ÷/100/47.1/44.1 0.665 (52)
4.1 100/63.3 0.025* 100/80.8 0.146 100/45.1 0.374
5.0 Nuclear polymorphism 84.0/64.4/60.0/52.0 0.147(125) 100/85.7/84.6/50.0 0.004 (62)* 33.3/42.1/40.0/50.0 0.767 (54)
5.1 71.4/56.4 0.097 92.3/69.6 0.018* 40.0/44.8 0.673
6.0 Nuclear polymorphism,
tumor front
66.7/75.0/68.8/57.5 0.507 (120) 100/94.7/64.2/64.7 0.054 (63) 20.0/46.7/40.0/54.5 0.363 (52)
6.1 72.9/62.5 0.302 96.2/75.0 0.029* 40.0/50.0 0.343
7.0 Perineural infiltration 70.0/52.9/28.6 0.003 (114)* 84.0/71.4/50.0 0.250 (59) 52.8/33.3/20.0 0.046 (50)*
7.1 70.0/45.8 0.020* 84.0/66.7 0.208 52.8/28.6 0.098
8.0 Lymphocytic infiltration 87.5/67.2/50.0 0.008 (123)* 100/87.5/56.3 0.003 (63)* 62.5/40.0/47.6 0.711 (54)
8.1 87.5/60.0 0.021* 100/77.1 0.050* 62.5/43.5 0.409
8.2 72.9/50.0 0.007* 91.5/56.3 0.001* 45.5/47.6 0.821
9.0 WPOI 100/70.6/82.8/58.9/56.3 0.190 (120) 100/80.0/100/77.8/66.7 0.224 (62) ÷/50.0/50.0/42.3/50.0 0.997 (52)
9.1 73.7/65.3 0.461 83.3/84.0 0.999 50,0/45.7 0.908
9.2 79.2/58.3 0.022* 93.1/75.8 0.061 50.0/44.4 0.902
*Significant at 0.05 level
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for the whole patient cohort. Grouping categories generates
larger groups for statistical analyses, and this can affect the
significance level. However, the cutoff for dichotomizing the
original three-tier variable was important. The variable only
had independent prognostic power when separating the tumors
with low lymphocytic infiltration from those with moderate and
abundant infiltration. This suggests that lymphocyte infiltration is
tightly related to the biology of the tumor and that the tumors
with little infiltration may take a more aggressive course. This is
in line with previous studies showing that a rich lymphocyte
infiltration is associated with favorable prognosis [24–26].
By incorporating the degree of differentiation and lymphocyt-
ic infiltration in a combined histo-score, we were able to define a
subgroup of patients with low-stage disease that had a much
lower survival rate than the rest of the low-stage disease patients.
Interestingly, the survival in this subgroup was even less favor-
able than patients with high-stage disease (42.9 versus 46.6%).
This indicates that patients with poorly differentiated tumors with
Fig. 1 Tumor differentiation and
lymphocyte infiltration. Well,
moderate, and poorly
differentiated tumor in a–c.
Marked, moderate, and little
lymphocyte infiltration in d–f
Fig. 2 Kaplan-Meier curve
showing the results after
combining the variables of
differentiation (1.0) and
lymphocytic infiltrate (8.0).
Scoring alternatives are shown in
Table 3. Patients with low score
(2–4) had a statistically better
survival than those with high
score (5–6). Figure 2 Kaplan-
Meier curve showing survival of
patients with low-stage disease
stratified according to the histo-
score
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a weak lymphocytic response should be regarded as high-risk
patients who need special attention, even if the tumors are small
and without lymph node metastases.
Perineural infiltration was a significant prognostic marker
for the whole cohort and for patients with high-stage disease,
but not for low-stage disease. One could assume that nerve
bundles are more abundant in deeper parts of the oral mucosa,
and tumors probably need to invade deeper than in T1 and T2
tumors for this to be a relevant marker. This illustrates the
importance of evaluating prognostic markers in homogenous
groups of tumors and controlling for known risk factors.
We found that alternative grading (fewer options) of histo-
pathological variables only altered their prognostic value only
to a minor extent. A previous study comparing inter- and intra-
rater agreement showed significantly better agreement when
using an alternative grading with fewer options, compared to
the more elaborate original grading [17]. This supports the use
of variables with fewer options as they improve the reproducibil-
ity of the scoring without reducing the prognostic power of the
variables. A simplification of scoring models has been intro-
duced for many cancers. The reproducibility for uterine endome-
trial endometrioid carcinoma was found to be higher with a bi-
nary tumor grading system [27]. In the latestWHO-classification
of tumors in theGI tract, the adenocarcinomas are stratified into a
two-tiered grading system, low-grade and high-grade, where
grading is based on the least differentiated component [28].
The present study is retrospective, and this approach gives a
larger risk of variation in how clinical variables are reported in
the electronic health records comparedwith prospective studies.
When subgrouping, some groups became small, which in-
creases the risk of underpowered statistical analyses and there-
by underestimating the prognostic power of some variables.
Our cohort included some tumors from which we had only
biopsy samples for histopathological evaluation, which makes
evaluation less certain. Therefore, we performed separate sta-
tistical analyses excluding the grading of biopsies (supplemen-
tary tables), but this did not alter the results significantly.
Conclusion
Our study on a large, homogenous tumor cohort of OTSCC
shows that a histo-score combining tumor differentiation and
lymphocytic infiltration identified a subgroup among the low-
stage disease patients that had lower DSS than the average
patients with high-stage disease. This subgroup should be giv-
en special consideration in treatment planning. Our results
also illustrate that many variables can be scored with fewer
options than previously suggested to increase their reproduc-
ibility, and still maintain their prognostic value.
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